BofA raised the firm’s price target on HealthEquity (HQY) to $125 from $110 and keeps a Buy rating on the shares following “a strong quarter” with revenue and EPS significantly exceeding Street expectations. The biggest focus heading into the quarter was the trajectory of fraud costs, but the firm notes that HealthEquity experienced less fraud costs each month in Q1 and believes the company has put in place “the right guardrails to slow this activity on the platform.” The firm’s higher multiple reflects greater confidence fraud costs are under control and underwrites some benefits from legislation not embedded in its estimates, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY:
- Healthequity’s Strong Financial Performance and Strategic Initiatives Drive Buy Rating
- HealthEquity price target raised to $117 from $110 at Citizens JMP
- Strong Financial Performance and Strategic Growth Opportunities Drive Buy Rating for Healthequity
- Healthequity’s Strong Financial Performance and Strategic Positioning Earns Buy Rating from Analyst
- HealthEquity, Inc. Reports Strong Q1 2026 Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue